Multiple Sclerosis: key endpoint results by drug

The key endpoints of Multiple Sclerosis trials, with each approved or late-stage drug's result from its own trial: the lead dose against placebo (or the trial's active comparator), the week, and the arm size. These are the same rows as the drug comparison, for every drug at once. To set chosen drugs side by side, with every shared endpoint, use the comparison. The drug list and pipeline are on the Multiple Sclerosis page.

Annualised relapse rate

Annualised relapse rate in Multiple Sclerosis: 15 drugs, each from its own trial
DrugResultControlDifferenceDose · week · nTrial
Abatacept0.10.1±0wk 24 · n 42NCT01116427 Phase 2, secondary
Alemtuzumab0.30.5 (Interferon Beta-1a)—12 mg · wk 104 · n 426NCT00548405 Phase 3, primary
Cladribine (MAVENCLAD®)0.10.3−0.25.25 mg/kg · wk 96 · n 456NCT00213135 Phase 3, primary
Copaxone0.30.4−0.1wk 104 · n 82NCT00451204 Phase 2, primary
Dimethyl fumarate (Tecfidera)0.20.4−0.2240 mg twice daily · wk 104 · n 359NCT00451451 Phase 3, primary
fingolimod (Gilenya)0.20.4−0.20.5 mg · wk 104 · n 425NCT00289978 Phase 3, primary
Interferon beta-1b0.20.3−0.1n 292NCT00185211 Phase 3, secondary
natalizumab0.51.7−1.2wk 24 · n 9NCT01440101 Phase 2/3, secondary
Ocrelizumab0.20.3 (Interferon Beta-1a)—wk 96 · n 410NCT01247324 Phase 3, primary
Ofatumumab0.10.3 (TER)—20 mg · n 469NCT02792231 Phase 3, primary
ozanimod0.20.3 (Interferon Beta-1a)—1 mg · wk 96 · n 433NCT02047734 Phase 3, primary
peginterferon beta-1a0.30.4−0.1every 4 weeks · wk 52 · n 500NCT00906399 Phase 3, primary
Ponesimod0.20.3 (Teriflunomide)—20 mg · wk 108 · n 567NCT02425644 Phase 3, primary
Tolebrutinib0.10.1 (Teriflunomide)—60 mg · wk 208 · n 486NCT04410978 Phase 3, primary
Ublituximab0.10.2 (Teriflunomide)—wk 96 · n 271NCT03277261 Phase 3, primary

Drugs checked with no result here: 34 not reported, 9 not posted, 8 trial running.

New or enlarging T2 lesions

New or enlarging T2 lesions in Multiple Sclerosis: 6 drugs, each from its own trial
DrugResultControlDifferenceDose · week · nTrial
fingolimod (Gilenya)2.59.8−7.30.5 mg · wk 104 · n 370NCT00289978 Phase 3, secondary
natalizumab0.31.1−0.8wk 24 · n 47NCT01440101 Phase 2/3, secondary
Ocrelizumab4301916 (Interferon Beta-1a)—wk 96 · n 410NCT01247324 Phase 3, secondary
ozanimod0.89−8.21 mg · wk 24 · n 83NCT01628393 Phase 2/3, secondary
peginterferon beta-1a7.910.9−3every 4 weeks · wk 52 · n 462NCT00906399 Phase 3, secondary
Tolebrutinib0.22.1−1.960 mg · n 31NCT03889639 Phase 2, secondary

Drugs checked with no result here: 37 not reported, 13 not posted, 10 trial running.

  1. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  2. Rows are in drug-name order, not ranked. Difference is the lead arm minus placebo, in the endpoint's unit. 66 approved or late-stage drugs with a featured trial in Multiple Sclerosis were checked; results come from ClinicalTrials.gov posted results unless marked. Updated 2026-11-19. How results are chosen: methodology.